JOP20220355A1 - مثبطات rip1k - Google Patents

مثبطات rip1k

Info

Publication number
JOP20220355A1
JOP20220355A1 JOJO/P/2022/0355A JOP20220355A JOP20220355A1 JO P20220355 A1 JOP20220355 A1 JO P20220355A1 JO P20220355 A JOP20220355 A JO P20220355A JO P20220355 A1 JOP20220355 A1 JO P20220355A1
Authority
JO
Jordan
Prior art keywords
inhibitors
rip1k
rip1
pharmaceutical formulations
kinase
Prior art date
Application number
JOJO/P/2022/0355A
Other languages
English (en)
Inventor
Mark Irving
Ihab Darwish
Rao Kolluri
Jiaxin Yu
Somasekhar Bhamidipati
Vanessa Taylor
Simon Shaw
Esteban Masuda
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of JOP20220355A1 publication Critical patent/JOP20220355A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات مثبطة للكيناز، مثل مركبات مثبطة لكيناز بروتين-1 متفاعل مع المستقبل (RIP1)، ويتعلق كذلك بتركيبات صيدلية وتوليفات تشتمل على تلك المركبات المثبطة. ويمكن استخدام المركبات و/أو التركيبات الصيدلية و/أو التوليفات التي يتم الكشف عنها لعلاج أو الوقاية من مرض أو حالة مرضية مرتبطة بالكيناز، وتحديدًا مرض أو حالة مرضية مرتبطة بـ RIP1.
JOJO/P/2022/0355A 2020-07-01 2022-12-29 مثبطات rip1k JOP20220355A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063047194P 2020-07-01 2020-07-01
PCT/US2021/039112 WO2022005898A1 (en) 2020-07-01 2021-06-25 Rip1k inhibitors

Publications (1)

Publication Number Publication Date
JOP20220355A1 true JOP20220355A1 (ar) 2022-12-29

Family

ID=76972022

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2022/0355A JOP20220355A1 (ar) 2020-07-01 2022-12-29 مثبطات rip1k

Country Status (21)

Country Link
US (2) US11667643B2 (ar)
EP (1) EP4175714A1 (ar)
JP (2) JP2023532718A (ar)
KR (2) KR20230033712A (ar)
CN (1) CN116209662B (ar)
AR (1) AR122703A1 (ar)
AU (1) AU2021300831B2 (ar)
BR (1) BR112022026908A2 (ar)
CA (1) CA3183296A1 (ar)
CL (1) CL2022003812A1 (ar)
CO (1) CO2023000051A2 (ar)
CR (1) CR20220685A (ar)
DO (1) DOP2022000300A (ar)
EC (1) ECSP22097749A (ar)
IL (1) IL299128A (ar)
JO (1) JOP20220355A1 (ar)
MX (1) MX2023000138A (ar)
PE (1) PE20230730A1 (ar)
PH (1) PH12022553615A1 (ar)
TW (2) TWI840311B (ar)
WO (1) WO2022005898A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3149926A1 (en) 2019-09-06 2021-03-11 Yan Chen Rip1 inhibitory compounds and methods for making and using the same
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
TWI840311B (zh) 2020-07-01 2024-04-21 美商雷傑製藥公司 Rip1k抑制劑
WO2023240379A1 (zh) * 2022-06-13 2023-12-21 南京医工医药技术有限公司 咪唑啉酮衍生物及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2192838A4 (en) 2007-08-15 2011-07-27 Harvard College HETEROCYCLIC NEKROPTOSIS HEMMER
AR079170A1 (es) * 2009-12-10 2011-12-28 Lilly Co Eli Compuesto de ciclopropil-benzamida-imidazo-benzazepina inhibidor de diacil-glicerol aciltransferasa, sal del mismo, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de obesidad o para mejorar la sensibilidad a insulina y compuesto intermedio par
TWI637951B (zh) 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
CN106573006A (zh) 2014-08-21 2017-04-19 葛兰素史密斯克莱知识产权发展有限公司 作为药物的rip1激酶抑制剂杂环酰胺
BR112017017411A2 (pt) 2015-02-13 2018-04-03 Glaxosmithkline Ip Dev Ltd Formas cristalinas de (s)-5-benzil-n-(5-metil-4-oxo- 2,3,4,5-tetraidrobenzo[b][1,4]oxazepin-3-il)-4h-1,2,4- triazol-3-carboxamida
EP3317269B1 (en) 2015-07-02 2022-09-21 F. Hoffmann-La Roche AG Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases
ES2885474T3 (es) 2015-10-13 2021-12-13 Inst Nat Sante Rech Med Derivados de sibirilina para la utilización en la prevención y/o tratamiento de trastornos asociados a la necroptosis celular
AU2016340527B2 (en) 2015-10-23 2020-09-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
IL287136B2 (en) 2016-02-05 2023-09-01 Denali Therapeutics Inc Receptor inhibitors - interacting with protein kinase 1
WO2018073193A1 (en) 2016-10-17 2018-04-26 F. Hoffmann-La Roche Ag Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
US20200062735A1 (en) 2017-02-27 2020-02-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CN111655678B (zh) 2018-01-05 2023-08-22 广州市恒诺康医药科技有限公司 细胞凋亡信号调节激酶-1抑制剂及其应用
MD3788045T2 (ro) 2018-05-03 2023-09-30 Rigel Pharmaceuticals Inc Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
HRP20231381T1 (hr) 2018-05-03 2024-03-01 Rigel Pharmaceuticals, Inc. Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
TW202019913A (zh) 2018-06-26 2020-06-01 中國科學院上海有機化學研究所 細胞壞死抑制劑及其製備方法和用途
CN111138448B (zh) 2018-11-02 2022-08-02 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
WO2020088194A1 (zh) 2018-11-02 2020-05-07 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
CA3149926A1 (en) 2019-09-06 2021-03-11 Yan Chen Rip1 inhibitory compounds and methods for making and using the same
JP7493586B2 (ja) 2019-09-06 2024-05-31 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
SI4055021T1 (sl) 2019-11-07 2026-02-27 Rigel Pharmaceuticals, Inc. Heterociklične spojine, ki inhibirajo rip1
BR112022010082A2 (pt) * 2019-11-26 2022-08-30 Univ Texas Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
TWI840311B (zh) 2020-07-01 2024-04-21 美商雷傑製藥公司 Rip1k抑制劑

Also Published As

Publication number Publication date
JP2025013995A (ja) 2025-01-28
TW202214225A (zh) 2022-04-16
CO2023000051A2 (es) 2023-04-17
TWI824259B (zh) 2023-12-01
TWI840311B (zh) 2024-04-21
US20230265100A1 (en) 2023-08-24
AR122703A1 (es) 2022-09-28
US20220009936A1 (en) 2022-01-13
WO2022005898A1 (en) 2022-01-06
DOP2022000300A (es) 2023-03-31
CR20220685A (es) 2023-03-28
IL299128A (en) 2023-02-01
KR20230033712A (ko) 2023-03-08
EP4175714A1 (en) 2023-05-10
ECSP22097749A (es) 2023-03-31
CN116209662A (zh) 2023-06-02
CA3183296A1 (en) 2022-01-06
CL2022003812A1 (es) 2023-08-18
AU2021300831B2 (en) 2024-11-07
BR112022026908A2 (pt) 2023-03-14
US11667643B2 (en) 2023-06-06
TW202408480A (zh) 2024-03-01
PH12022553615A1 (en) 2024-03-04
MX2023000138A (es) 2023-04-11
PE20230730A1 (es) 2023-05-03
JP2023532718A (ja) 2023-07-31
US12297202B2 (en) 2025-05-13
KR20260023108A (ko) 2026-02-20
CN116209662B (zh) 2026-01-27
AU2021300831A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
JOP20230272A1 (ar) مركبات تثبيط rip1 وطرق لتحضير واستخدامها
JOP20200277B1 (ar) مركبات تثبيط rip1 وطرق لتحضير واستخدامها
MX2025011774A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
JOP20220355A1 (ar) مثبطات rip1k
SA522431867B1 (ar) مثبطات كيناز بروتين-1 المتفاعل مع المستقبل غير متجانسة الحلقات
JOP20220056A1 (ar) مركبات rip1 تثبيطية وطرق عملها واستخدامها
MX2022000711A (es) Inhibidores de parp1.
MX2020014245A (es) Inhibidores de quinasas dependientes de ciclinas.
PH12022552638A1 (en) Rip1k inhibitors
MX379155B (es) Compuestos que inhiben la proteína mcl-1.
EP4285906A3 (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
WO2019152419A8 (en) Prc2 inhibitors
CL2011000489A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
ZA202301066B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
AU2018284249A1 (en) Aminothiazole compounds as protein kinase inhibitors
WO2020106751A8 (en) Inhibitors of gli1 as therapeutic agents
JOP20230213A1 (ar) مثبطات حلقية غير متجانسة لكيناز البروتين المتفاعل مع المستقبل-1
MX2022004639A (es) Compuestos biciclicos que contienen nitrogeno.